Targeted Medicine builds on our growing understanding of how genetics affects the causes, progression and treatment of disease as well as the contribution of genomics to the discovery, development and commercialization of drugs.

How We Develop Targeted Medicines

Optimize the efficacy and reduce the side-effects of therapeutic compounds

• Using genotyping, gene expression analysis and bioinformatics to identify genetic markers linked to the disease, we can differentiate subject populations in clinical trials by testing for genetic differences that will affect individual response to the drug. This stratification allows us to select subjects who are genetically more likely to respond to the test drug, or less likely to experience adverse effects.

Increase the likelihood of clinical success and reduce clinical cost

• We use genetic information to identify patients who are more likely to respond to a drug in order to increase the probability of clinical success, reduce the cost and shorten the timeframe of our clinical programs. It currently takes between 10-15 years and costs approximately $802 million to develop and gain approval for a new prescription drug in the United States. This high cost is associated with the high failure rate of drugs in development, with only one in ten drug candidates tested in humans receiving regulatory approval. By focusing on the patients more likely to respond to a drug, we are striving to significantly increase our changes of clinical success while at the same time reducing the time and cost it takes to gain marketing approval.

Facilitate the discovery of drugs that will intervene in disease development

• We use our proprietary databases, target screening systems and our animal models to discover and validate promising genetic targets for drug treatment. Development efforts at ChemGenex seek to yield drugs directed against various genetic targets involved in a range of cancers.